{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:23:35Z","timestamp":1720484615573},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11523-024-01074-9","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T08:15:06Z","timestamp":1720080906000},"page":"483-494","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Shilpa","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen H.-S.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"1074_CR1","unstructured":"American Cancer Society. Survival Rates for Bladder Cancer. https:\/\/www.cancer.org\/cancer\/bladder-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed 5 Apr 2024."},{"key":"1074_CR2","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. V2.2024."},{"issue":"1","key":"1074_CR3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2021","unstructured":"Cathomas R, Lorch A, Bruins HM, et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2021;81(1):95\u2013103.","journal-title":"Eur Urol"},{"issue":"3","key":"1074_CR4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358.","journal-title":"Ann Oncol"},{"issue":"10","key":"1074_CR5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"1","key":"1074_CR6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41(1):22\u201331.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1074_CR7","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O'Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023;41(25):4107\u201317.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1074_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.22.01992","volume":"41","author":"ER Plimack","year":"2022","unstructured":"Plimack ER, Zibelman MR. Platinum-free systemic therapy in first-line metastatic urothelial carcinoma: mirage or oasis in the platinum desert? J Clin Oncol. 2022;41(1):7\u201310.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1074_CR9","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.23.00987","volume":"41","author":"AO Siefker-Radtke","year":"2023","unstructured":"Siefker-Radtke AO, Cauley D, Alhalabi O. Combinations, sequencing, and the contribution of components: new frontline standards for metastatic urothelial carcinoma. J Clin Oncol. 2023;41(25):4084\u20136.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1074_CR10","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904.","journal-title":"World J Urol"},{"issue":"Suppl 11","key":"1074_CR11","doi-asserted-by":"crossref","first-page":"Abstract 11","DOI":"10.1200\/OP.2023.19.11_suppl.11","volume":"19","author":"C Ike","year":"2023","unstructured":"Ike C, Kongnakorn T, Tichy E, et al. Healthcare costs associated with first-line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma (la\/mUC) in the United States (US). J Oncol Pract. 2023;19(Suppl 11):Abstract 11.","journal-title":"J Oncol Pract"},{"key":"1074_CR12","unstructured":"National Comprehensive Cancer Network. NCCN Best Practices Committee: drug shortage follow-up survey results. October 5, 2023. https:\/\/www.nccn.org\/docs\/default-source\/oncology-policy-program\/NCCN-Drug-Shortages-Survey-Update.pdf. Accessed 5 Apr 2024."},{"issue":"2","key":"1074_CR13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","volume":"29","author":"A Bamias","year":"2018","unstructured":"Bamias A, Tzannis K, Harshman LC, et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive\/advanced cancer of the urothelium (RISC). Ann Oncol. 2018;29(2):361\u20139.","journal-title":"Ann Oncol"},{"key":"1074_CR14","unstructured":"Keytruda (pembrolizumab). Prescribing information. MSD, Kenilworth, NJ, USA; 2024."},{"issue":"17","key":"1074_CR15","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1074_CR16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211\u20134.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1074_CR17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","volume":"18","author":"DM Jiang","year":"2021","unstructured":"Jiang DM, Gupta S, Kitchlu A, et al. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021;18(2):104\u201314.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1074_CR18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-015-2774-z","volume":"76","author":"YR Kim","year":"2015","unstructured":"Kim YR, Lee JL, You D, et al. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma. Cancer Chemother Pharmacol. 2015;76(1):141\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1074_CR19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.21873\/invivo.11454","volume":"33","author":"K Izumi","year":"2019","unstructured":"Izumi K, Iwamoto H, Yaegashi H, et al. Gemcitabine plus cisplatin split versus gemcitabine plus carboplatin for advanced urothelial cancer with cisplatin-unfit renal function. In Vivo. 2019;33(1):167\u201372.","journal-title":"In Vivo"},{"issue":"12","key":"1074_CR20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.ejca.2012.04.002","volume":"48","author":"R Morales-Barrera","year":"2012","unstructured":"Morales-Barrera R, Bellmunt J, Su\u00e1rez C, et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012;48(12):1816\u201321.","journal-title":"Eur J Cancer"},{"issue":"Suppl 16","key":"1074_CR21","doi-asserted-by":"crossref","first-page":"Abstract 4577","DOI":"10.1200\/JCO.2022.40.16_suppl.4577","volume":"40","author":"S Gupta","year":"2022","unstructured":"Gupta S, Bellmunt J, Plimack ER, et al. Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC). J Clin Oncol. 2022;40(Suppl 16):Abstract 4577.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1074_CR22","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1074_CR23","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1074_CR24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G, et al. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191\u20139.","journal-title":"J Clin Oncol"},{"key":"1074_CR25","unstructured":"Bavencio (avelumab). Prescribing information. EMD Serono, Rockland, MA, USA, an affiliate of Merck KGaA; 2023."},{"issue":"13","key":"1074_CR26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330.","journal-title":"N Engl J Med"},{"issue":"19","key":"1074_CR27","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up. J Clin Oncol. 2023;41(19):3486\u201392.","journal-title":"J Clin Oncol"},{"key":"1074_CR28","volume":"27","author":"U Swami","year":"2021","unstructured":"Swami U, Grivas P, Pal SK, et al. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience. Cancer Treat Res Commun. 2021;27:100325.","journal-title":"Cancer Treat Res Commun."},{"issue":"5","key":"1074_CR29","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2021.11.014","volume":"40","author":"DM Geynisman","year":"2022","unstructured":"Geynisman DM, Broughton E, Hao Y, et al. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol Oncol. 2022;40(5):195.e1-e11.","journal-title":"Urol Oncol"},{"issue":"Suppl 16","key":"1074_CR30","doi-asserted-by":"crossref","first-page":"Astract 4565","DOI":"10.1200\/JCO.2022.40.16_suppl.4565","volume":"40","author":"GP Sonpavde","year":"2022","unstructured":"Sonpavde GP, Galsky MD, Wright P, et al. Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma. J Clin Oncol. 2022;40(Suppl 16):Astract 4565.","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"1074_CR31","first-page":"Abstract 704P","volume":"32","author":"AK Morgans","year":"2021","unstructured":"Morgans AK, Galsky MD, Hepp Z, et al. Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA. Ann Oncol. 2021;32(Suppl 5):Abstract 704P.","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"1074_CR32","doi-asserted-by":"crossref","first-page":"Abstract 472","DOI":"10.1200\/JCO.2020.38.6_suppl.472","volume":"38","author":"K Rosenthal","year":"2020","unstructured":"Rosenthal K, Galsky MD, Milowsky MI, et al. Practice trends and attitudes of medical oncologists on new therapies in urothelial carcinoma. J Clin Oncol. 2020;38(Suppl 6):Abstract 472.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1074_CR33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","volume":"23","author":"MD Galsky","year":"2012","unstructured":"Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23(2):406\u201310.","journal-title":"Ann Oncol"},{"issue":"6","key":"1074_CR34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.euf.2022.02.007","volume":"8","author":"K Mori","year":"2022","unstructured":"Mori K, Schuettfort VM, Yanagisawa T, et al. Reassessment of the efficacy of carboplatin for metastatic urothelial carcinoma in the era of immunotherapy: a systematic review and meta-analysis. Eur Urol Focus. 2022;8(6):1687\u201395.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"1074_CR35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.euf.2021.08.009","volume":"8","author":"A Richters","year":"2022","unstructured":"Richters A, Boormans JL, van der Heijden MS, et al. Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study. Eur Urol Focus. 2022;8(4):995\u20131002.","journal-title":"Eur Urol Focus"},{"key":"1074_CR36","unstructured":"Tecentriq (atezolizumab). Prescribing information. Genentech, Inc., South San Francisco, CA, USA; 2023."},{"issue":"10236","key":"1074_CR37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija JAA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547\u201357.","journal-title":"Lancet"},{"issue":"7","key":"1074_CR38","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Csoszi T, Ozguroglu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931\u201345.","journal-title":"Lancet Oncol"},{"key":"1074_CR39","unstructured":"Padcev (enfortumab vedotin-ejfv). Prescribing information. Astellas Pharma US, Inc., Northbrook, IL, USA; 2024."},{"key":"1074_CR40","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389(19)","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389.","journal-title":"N Engl J Med"},{"key":"1074_CR41","unstructured":"Opdivo (nivolumab). Prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA; 2024."},{"issue":"Suppl 2","key":"1074_CR42","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2023.10.107","volume":"34","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde GP, Powles TB, et al. Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial. Ann Oncol. 2023;34(Suppl 2):S1341 (abstract LBA7).","journal-title":"Ann Oncol"},{"issue":"4","key":"1074_CR43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jnci\/djad246","volume":"116","author":"S Gupta","year":"2024","unstructured":"Gupta S, Andreev-Drakhlin A, Fajardo O, et al. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment. J Natl Cancer Inst. 2024;116(4):547\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 6","key":"1074_CR44","doi-asserted-by":"crossref","first-page":"Abstract 457","DOI":"10.1200\/JCO.2022.40.6_suppl.457","volume":"40","author":"N Milloy","year":"2022","unstructured":"Milloy N, Kirker M, Berry M, et al. Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5). J Clin Oncol. 2022;40(Suppl 6):Abstract 457.","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"1074_CR45","doi-asserted-by":"crossref","first-page":"Abstract TPS589","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS589","volume":"41","author":"H Nagar","year":"2023","unstructured":"Nagar H, Ballman KV, Tagawa ST, et al. Alliance A032002 (ART): phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible\/refractory metastatic urothelial cancer. J Clin Oncol. 2023;41(Suppl 6):Abstract TPS589.","journal-title":"J Clin Oncol"},{"key":"1074_CR46","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0298","author":"M Kearney","year":"2023","unstructured":"Kearney M, Zhang L, Hubscher E, et al. Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis. Future Oncol. 2024;20(16):1123\u201337.","journal-title":"Future Oncol"},{"issue":"8","key":"1074_CR47","doi-asserted-by":"crossref","first-page":"357e11","DOI":"10.1016\/j.urolonc.2023.03.012","volume":"41","author":"AK Morgans","year":"2023","unstructured":"Morgans AK, Galsky MD, Wright P, et al. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility. Urol Oncol. 2023;41(8):357e11-e21.","journal-title":"Urol Oncol"},{"issue":"10064","key":"1074_CR48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67\u201376.","journal-title":"Lancet"},{"issue":"23","key":"1074_CR49","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","volume":"38","author":"J Vuky","year":"2020","unstructured":"Vuky J, Balar AV, Castellano D, et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2020;38(23):2658\u201366.","journal-title":"J Clin Oncol"},{"key":"1074_CR50","doi-asserted-by":"crossref","unstructured":"Loriot Y, Csoszi T, Matsubara N, et al. Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011. Ann Oncol. 2022;33(Suppl 7):S1339 (abstract 752P).","DOI":"10.1016\/j.annonc.2022.07.1830"},{"key":"1074_CR51","unstructured":"Keytruda (pembrolizumab). Summary of product characteristics. MSD, Haarlem, The Netherlands; 2022."},{"key":"1074_CR52","unstructured":"Tecentriq (atezolizumab). Summary of product characteristics. Roche Registration GmbH, Grenzach-Wyhlen, Germany; 2023."},{"key":"1074_CR53","unstructured":"Genentech. Genentech provides update on Tecentriq US indication for previously untreated metastatic bladder cancer. https:\/\/www.gene.com\/media\/statements\/ps_112822. Accessed 5 Apr 2024."},{"issue":"12","key":"1074_CR54","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574\u201388.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1074_CR55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.eururo.2023.08.001","volume":"85","author":"SS Sridhar","year":"2024","unstructured":"Sridhar SS, Powles T, Climent Duran MA, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN Bladder 100 by duration of first-line chemotherapy and interval before maintenance. Eur Urol. 2024;85(2):154\u201363.","journal-title":"Eur Urol"},{"key":"1074_CR56","doi-asserted-by":"crossref","first-page":"S1207","DOI":"10.1016\/j.annonc.2023.09.1020","volume":"34","author":"S Gupta","year":"2023","unstructured":"Gupta S, Climent Duran MA, Sridhar S, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts). Ann Oncol. 2023;34:S1207 (abstract 2371P).","journal-title":"Ann Oncol"},{"issue":"4","key":"1074_CR57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","volume":"83","author":"P Grivas","year":"2023","unstructured":"Grivas P, Kopyltsov E, Su PJ, et al. Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma. Eur Urol. 2023;83(4):320\u20138.","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"1074_CR58","doi-asserted-by":"crossref","first-page":"Abstract 4559","DOI":"10.1200\/JCO.2022.40.16_suppl.4559","volume":"40","author":"B P\u00e9rez-Valderrama","year":"2022","unstructured":"P\u00e9rez-Valderrama B, Powles T, Sridhar SS, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy. J Clin Oncol. 2022;40(16_suppl):Abstract 4559.","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"1074_CR59","first-page":"Abstract TPS460","volume":"40","author":"S Gupta","year":"2022","unstructured":"Gupta S, Ballman KV, Galsky MD, et al. MAIN-CAV: phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001). J Clin Oncol. 2022;40(Suppl 16):Abstract TPS4607.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1074_CR60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/fon-2023-0492","volume":"20","author":"J Hoffman-Censits","year":"2024","unstructured":"Hoffman-Censits J, Grivas P, Powles T, et al. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. Future Oncol. 2024;20(4):179\u201390.","journal-title":"Future Oncol"},{"key":"1074_CR61","unstructured":"ISRCTN Registry. A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer (DISCUS). https:\/\/www.isrctn.com\/ISRCTN15750433. Accessed 5 Apr 2024."},{"issue":"11","key":"1074_CR62","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"6","key":"1074_CR63","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970\u20136.","journal-title":"Ann Oncol"},{"issue":"3","key":"1074_CR64","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1074_CR65","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35(19):2117\u201324.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1074_CR66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51\u201364.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1074_CR67","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961\u201371.","journal-title":"N Engl J Med"},{"issue":"4","key":"1074_CR68","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"1074_CR69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","volume":"35","author":"AO Siefker-Radtke","year":"2024","unstructured":"Siefker-Radtke AO, Matsubara N, Park SH, et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024;35(1):107\u201317.","journal-title":"Ann Oncol"},{"issue":"22","key":"1074_CR70","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474\u201385.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1074_CR71","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872\u201382.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1074_CR72","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"Suppl 16","key":"1074_CR73","doi-asserted-by":"crossref","first-page":"Abstract 4560","DOI":"10.1200\/JCO.2022.40.16_suppl.4560","volume":"40","author":"J Bellmunt","year":"2022","unstructured":"Bellmunt J, Powles T, Duran MAC, et al. Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: exploratory analyses from JAVELIN Bladder 100. J Clin Oncol. 2022;40(Suppl 16):Abstract 4560.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1074_CR74","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/annonc\/mdt007","volume":"24","author":"J Bellmunt","year":"2013","unstructured":"Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24(6):1466\u201372.","journal-title":"Ann Oncol"},{"issue":"22","key":"1074_CR75","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"1074_CR76","doi-asserted-by":"crossref","first-page":"Abstract LBA531","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531","volume":"42","author":"AB Apolo","year":"2024","unstructured":"Apolo AB, Ballman KV, Sonpavde GP, et al. AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. J Clin Oncol. 2024;42(Suppl 4):Abstract LBA531.","journal-title":"J Clin Oncol"},{"key":"1074_CR77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.critrevonc.2017.10.012","volume":"120","author":"Y Urun","year":"2017","unstructured":"Urun Y, Leow JJ, Fay AP, et al. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;120:120\u20136.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01074-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:13:44Z","timestamp":1720458824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01074-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"17 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This podcast was funded by Merck (CrossRef Funder ID: 10.13039\/100009945).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors received no honoraria related to the development of this publication. Shilpa Gupta has served in consulting or advisory roles for Bayer, Bristol Myers Squibb, Gilead Sciences, Guardant Health, Merck, MSD, Pfizer, and Seagen; has reported speakers services for Astellas Pharma, Bristol Myers Squibb, Gilead Sciences, Janssen Oncology, and Seagen; and has stock and other ownership interests in BioNTech and Nektar Therapeutics. Helen H.-S. Moon has received honoraria from Merck and Pfizer and has received institutional research funding from Amgen, Apollomics, Arcus Biosciences, AVEO, Bristol Myers Squibb, Genentech, HUYA Bioscience International, Nektar, Prometheus, Revimmune, and Seagen. Srikala S. Sridhar has served in consulting or advisory roles for their institution for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, MSD, Pfizer, Roche\/Genentech, and Seagen and has received institutional research funding from Bayer, Janssen, and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Shilpa Gupta, Helen H.S. Moon, and Srikala S. Sridhar contributed equally to all aspects of the development of this podcast, including concept and design, drafting of the outline, and interpretation of the data discussed.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}